Price history
¥4,349Latest+30.6%
Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview
Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.
Companies sharing a theme
News
Key numbersShowing 8 of 20
PER
78.67How many years of earnings it would take to buy the stock. The market average is generally considered to be around 15.PBR
1.47How many times the company's net assets? Around 1x is generally considered a benchmark.ROE
1.9%Earning power. A figure above 10% is generally considered good.Dividend yield
0.0%The annual dividend as a percentage of the share price.Market capitalization
¥1.2tnShare price × number of shares. The value of the entire company.Equity ratio
60.1%The proportion of assets funded by money that does not have to be repaid.Operating margin
7.8%The percentage of revenue remaining from the company’s core business.Revenue growth (3 years)
3.3%The average annual growth in sales over the past three years.What to watch next
Progress of the Japan Fair Trade Commission's investigation into suspected coordination of ice cream selling prices, including whether sanctions or corrective measures are imposed and whether additional disclosure is made
Unknown, depending on the progress of the response to the authoritiesImpact HighLikelihood Medium
Disclosure of how much shipments and supply performance for KOSTAIVE intramuscular injection, a next-generation mRNA vaccine supplied in two-person vials, contributed to the increase in routine vaccinations
Results disclosed with the next earnings release or interim resultsImpact MediumLikelihood Medium
Clinical and development milestones for pharmaceutical investment themes, including KD-414, such as Phase 3 progress and updates on co-development
Unknown, depending on the clinical scheduleImpact MediumLikelihood Low
Confirmation of progress against the medium-term plan, including Integrated ROESG, consolidated operating profit, overseas sales, ROIC/ROE and the total payout ratio, together with evidence supporting margin improvement
Updates through fiscal 2026 plan management and the earnings periodImpact MediumLikelihood Medium
What to watch next
Who owns itTop holders total 35.7%
Listed holders 35.7%Everyone else 64.3%
The Master Trust Bank of Japan (Trust Account)15.40%
Custody Bank of Japan, Ltd. (Trust Account).5.43%
Nippon Life Insurance Company (standing proxy: The Master Trust Bank of Japan, Ltd.)2.40%
The Norinchukin Bank2.07%
明治ホールディングス従業員持株会1.99%
STATE STREET BANK WEST CLIENT - TREATY 5052341.98%
明治ホールディングス取引先持株会1.90%
㈱みずほ銀行(常任代理人 日本カストディ銀行)1.73%
2 other listed holders2.77%
| Holder | Ownership (%) |
|---|---|
| The Master Trust Bank of Japan (Trust Account) | 15.40 |
| Custody Bank of Japan, Ltd. (Trust Account). | 5.43 |
| Nippon Life Insurance Company (standing proxy: The Master Trust Bank of Japan, Ltd.) | 2.40 |
| The Norinchukin Bank | 2.07 |
| 明治ホールディングス従業員持株会 | 1.99 |
| STATE STREET BANK WEST CLIENT - TREATY 505234 | 1.98 |
| 明治ホールディングス取引先持株会 | 1.90 |
| ㈱みずほ銀行(常任代理人 日本カストディ銀行) | 1.73 |
| 2 other listed holders | 2.77 |
This company's documents
Filings
Timely disclosures
- 2026-10-06Notice Regarding Change in Consolidated Subsidiary (Share Transfer)
- 2026-09-30Execution of a Joint Venture Agreement and Share Transfer Agreement for the Transfer of Kyorin Pharmaceutical's Generic Drug Business to a Jointly Owned Company to Be Established by ダイト, Meiji Seika Pharma and Development Bank of Japan
- 2026-09-25Notice Regarding Completion of Payment for the Disposal of Treasury Shares Under an Incentive Plan Using Restricted Stock for Employees and Partial Forfeiture
- 2026-09-04Articles of Incorporation 2026/06/26
- 2026-08-31Notice of the Publication of the "Integrated Report 2026"
- 2026-08-05Financial Results for the First Quarter of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated)
- 2026-07-31Notice Regarding Completion of Payment for the Disposal of Treasury Shares as Restricted Stock-Based Compensation for Directors and Officers
- 2026-07-21Notice Regarding the Transfer of Shares in a Subsidiary in Connection with the Restructuring of the China Business Portfolio
11 more
- 2026-07-03Notice Regarding the Disposal of Treasury Shares under an Incentive Scheme Using Restricted Stock for Employees
- 2026-07-03Notice Concerning the Disposal of Treasury Shares as Restricted Stock Compensation for Directors and Executive Officers
- 2026-06-26Report on Corporate Governance 2026/06/26
- 2026-05-2917th Annual General Meeting of Shareholders: Other Matters Subject to Electronic Provision (Matters Omitted from Delivered Documents)
- 2026-05-29Business Report and Other Documents for the 17th Annual General Meeting of Shareholders
- 2026-05-29Notice of Convocation of the 17th Annual General Meeting of Shareholders
- 2026-05-21Notice Regarding Dividend from Retained Earnings
- 2026-05-14Notice Regarding Partial Amendments to the Articles of Incorporation
- 2026-05-14Notice Concerning the Board of Directors’ Opinion on the Shareholder Proposal
- 2026-05-14Summary of Financial Results for the Fiscal Year Ending March 2026 [Japanese GAAP] (Consolidated)
- 2026-03-25Notice Regarding the Recognition of Extraordinary Losses (Impairment Losses) and Revisions to Consolidated Earnings Forecasts
Threads
- 2026-10-16Improving Logistics Efficiency and Reducing Environmental Impact Through Sea and Round-Trip Transport with Nestlé Japan
- 2026-10-13Group Management Centered on a Pure Holding Company
- 2026-10-13Absorption-type merger of 四国明治 and change in the consolidation scope for a Chinese pharmaceutical subsidiary
- 2026-10-06Expanding share in core food categories and transforming the business structure
- 2026-09-25Introduction of a restricted stock compensation plan
- 2026-09-04Soaring raw material prices and other factors
- 2026-09-04Impairment Risk for Fixed Assets and Goodwill
- 2026-08-05Strengthening earnings capacity to respond to changes in the business environment
106 more
- 2026-08-05Promotion of Global Expansion
- 2026-07-21Strengthening the raw milk procurement value chain in China through an investment in AustAsia
- 2026-07-21AustAsia Profitability Deterioration and Impairment Risk Due to Oversupply of Raw Milk in China
- 2026-06-26Advancing the Management Foundation
- 2026-06-26Swift Decision-Making and Highly Transparent Management
- 2026-06-26Strengthening Oversight through Outside Directors, Outside Audit & Supervisory Board Members and the Nomination and Compensation Committee
- 2026-06-26Group-Wide Internal Controls and Risk Management Framework
- 2026-06-24Globalization of the Pharmaceutical Business through Overseas Subsidiaries and メドライク社
- 2026-06-24Expansion of the pharmaceutical, agrochemical and veterinary drug R&D pipeline
- 2026-06-24Stable, Sustained Shareholder Returns and a Consolidated Payout Ratio Target of 30%
- 2026-06-24Planned next annual dividend: ¥90
- 2026-06-24A New Challenge in the Health Value Sector
- 2026-06-24Contributing to the Resolution of Social Issues and Building a Sustainable Society
- 2026-06-24Stable Supply of Biological Products and Contributions to Public Health
- 2026-06-24Determination of Whether to Continue or Reduce Strategic Shareholdings
- 2026-06-24Development and Commercialization of Novel Coronavirus Vaccines
- 2026-06-24Rapid Advances in Digital Technology, Therapies and Manufacturing Methods
- 2026-06-24Addressing Climate Change and Its Impacts
- 2026-06-24TCFD-Aligned Climate Change Scenario Analysis and Disclosure
- 2026-06-242023 Medium-Term Management Plan: "Meiji ROESG Management"—Achieving Profit Growth and Sustainability Simultaneously
- 2026-06-24Strengthening Management through the Use of ROIC
- 2026-06-24Downward Revision to Consolidated Performance Plan Figures for FY2021
- 2026-06-24Returning to a Growth Trajectory Under the 2026 Medium-Term Management Plan and Advancing Meiji’s ROESG Management
- 2026-06-24Stable Supply of Antibiotics and Establishment of an API Production System
- 2026-06-24Consortium to Resolve Supply Concerns for Generic Drugs
- 2026-06-24Construction of a Dairy Products Production Plant in the Konsen Area
- 2026-06-24Talent Deployment Based on Jobs and Roles Under the New Personnel System
- 2026-06-24Antitrust Law Investigation into Ice Cream Retail Prices
- 2026-06-24Natural Capital Analysis Using the TNFD and LEAP Approach
- 2026-06-24Construction of the New Kanagawa Plant
- 2026-06-24Expansion of Confectionery Production Facilities at D.F. Stauffer Biscuit Co. in the United States
- 2026-06-24Transfer of shares in KM Biologics to Meiji Seika Pharma
- 2026-05-29Sustained Growth Driven by Specialty and Generic Pharmaceuticals
- 2026-05-29Balancing Continued Investment for Growth with the Construction of a Strong Financial Base
- 2026-05-14Expanding health-value products centered on fermented dairy and nutrition
- 2026-05-14食品・医薬品の二事業セグメント体制
- 2026-05-14Impact of Drug Price Revisions and Healthcare Policy
- 2026-05-14Returning profits and improving capital efficiency through share repurchases
- 2026-03-25Impact of Business Globalization
- 2025-06-26Food Safety, Product Recall and Reputational Risk
- 2025-06-26Natural Disasters, Damage to Social Infrastructure, and Infectious Disease Outbreaks
- 2025-06-26Sustainable Sourcing, Human Rights Due Diligence and Advancing Diversity
- 2025-06-26Talent Development, Employee Engagement and Workplace Environment
- 2025-06-26Promotion of D&I, Health Management and Talent Development by the Group Talent Committee
- 2025-06-26Increase in estimated returns due to the decline in influenza vaccination rates
- 2025-06-26Company-wide sustainability governance structure led by the CSO and Sustainability Committee
- 2025-06-26Business Partnership with Seqirus for Products Manufactured in Japan
- 2025-06-26Standardization of Fiscal Year-End Dates for Overseas Consolidated Subsidiaries and Other Entities, and Consolidation Based on Provisional Financial Statements
- 2025-06-26Reorganization of Revenue Disaggregation Categories for Food and Pharmaceutical Products
- 2025-06-26Application of Accounting Standards for Income Taxes
- 2025-06-26¥50 billion ESG investment allocation under the 2026 Medium-Term Management Plan
- 2025-06-26Nutritional Value Assessment and Product Development Using Meiji NPS (Meiji’s nutrition profiling system)
- 2025-06-26Market-creating product development under Meiji's Sustainable Products Certification System
- 2025-06-26Planned application of the new lease accounting standard from the fiscal year ending March 2028
- 2024-11-112026 Vision “Beyond meiji: Toward a Meiji Beyond Imagination”
- 2024-02-09Strengthening competitive businesses and taking on new growth opportunities
- 2024-02-09Low-cost operations across domestic and overseas production sites
- 2024-02-09Downturn in overseas economic conditions and uncertainty over domestic personal consumption
- 2024-02-09Decline in Sales Volume Due to Price Revisions
- 2023-06-29Information Leaks, Tampering and System Outages
- 2023-06-29Lower yogurt and probiotic sales amid intensifying competition among health-benefit products
- 2023-06-29Lowering the Investment Unit and Improving Liquidity Through a Stock Split
- 2023-06-29Cessation of Research Functions at the Yokohama Research Institute and Consolidation at the Ashigara Pharmaceutical Research Institute
- 2023-02-10Establishment of a New Municipal Milk Production Plant in Eniwa City
- 2022-11-09Adoption of the accounting standards for fair value measurement
- 2022-08-10Integration of the Animal Pharmaceuticals Business and Veterinary Vaccines Business
- 2022-06-29Food safety and security, and strengthening the quality-assurance framework
- 2022-06-29Impact of Weather on Food Demand
- 2022-06-29Unexpected Adverse Drug Reactions
- 2022-06-29Prolongation, Interruption, and Discontinuation of Pharmaceutical R&D
- 2022-06-29Funding-Related Liquidity Risk
- 2022-06-29Sustainability Finance Framework and 10th Sustainability Bond
- 2022-02-10Concentration of management resources on prescription pharmaceuticals through the transfer of the agricultural chemicals business
- 2021-11-10Application of the Revenue Recognition Accounting Standard from the Fiscal Year Ending March 2022
- 2021-11-10Concentrating Resources on Biopharmaceutical Development Through the Transfer of DM Bio's Ownership Interest
- 2021-08-12Growth and Profitability Improvement Targets under the 2020 Medium-Term Management Plan
- 2021-02-10Employee Safety and Stable Supply Measures in Response to COVID-19
- 2021-02-10Changes in Customer Values, Abandoned Product Launches and Rumors About Ingredients
- 2020-06-26New chocolate production equipment at the Sakado Plant and new protein plant in Okayama
- 2020-06-26Establishment of an Additional Issuance Limit for Domestic Unsecured Straight Bonds
- 2020-06-26Construction of new powdered milk production facilities at the Saitama Plant
- 2020-06-26Profit concentration in a specific product
- 2020-02-07Sales decline for the antidepressant “Reflex” following patent expiry
- 2020-02-07KM Biologics' operating loss due to seasonal factors
- 2020-02-07Adoption of IFRS 16, Leases, by Overseas Consolidated Subsidiaries
- 2019-06-27Changes in the Regulatory and Operating Environment Surrounding the Dairy Farming and Dairy Products Industry
- 2019-06-27Litigation Involving Third-Party Intellectual Property Rights
- 2019-06-27Change in the Depreciation Method for Building Improvements and Structures
- 2019-06-27Stabilizing Financing and Reducing Financing Costs through a Group Financing System
- 2019-06-27Impact of Changes to the Trading System on Ice Cream Sales
- 2019-06-27Strengthening KMバイオロジクス’ Governance, Legal Compliance, and Quality and Production Management Framework
- 2019-06-27Recognition of Impairment Losses on Medreich and Other Assets
- 2018-11-09Investment in and Consolidation of the Company Succeeding to the Main Business of Chemo-Sero-Therapeutic Research Institute
- 2018-06-28A company providing food and health value under the 2020 Vision
- 2018-06-28STEP UP 17 targets for accelerating growth and improving profitability
- 2018-06-28New Research Institute and Cheese Production Facilities at the Tokachi Plant
- 2018-06-28Shareholder returns through the acquisition of treasury shares to commemorate the company’s 100th anniversary since its founding
- 2018-06-28Growth and Development into One of the World’s Leading Corporate Groups
- 2018-06-28Creating Value as a Food and Health Professional
- 2018-06-28Five management principles centered on customers, safety and security, and value creation
- 2018-06-28Funding Through a Bond Issue for the Pharmaceutical Business
- 2018-02-09Decline in antibiotic sales due to generic market penetration
- 2018-02-09Declining demand in certain food categories due to weak market conditions
- 2018-02-09Declining Infant Formula Demand Due to Falling Births and Market Contraction
- 2017-11-10Declining Beauty Product Sales Due to Weaker Inbound Demand
- 2017-06-29Shortening of Asset Useful Lives in Connection with Head Office and Research Institute Relocation